Earnings release · MRK
Merck & Co., Inc. · Filed · SEC Form 8-K, Item 2.02
EPS was $2.04. The company issued new guidance, which gives a first marker for expectations in the periods ahead.
Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.
$2.04
…ting Principles (GAAP) earnings per share (EPS) assuming dilution was $2.04 and non-GAAP EPS was $2.49.…
Guidance issued
…Full-Year 2026 Financial Outlook - Narrows and Raises the Midpoint of Worldwide Sales Range; Now Expects Sales To Be Between $66.8 Billion and $67.3 Billion. 1 Available in some markets as KEYTRUDA…
| Previous (Aug 4) | This release | Change | |
|---|---|---|---|
| Revenue growth (YoY) | — | — | — |
| EPS growth (YoY) | — | — | — |
| Guidance | issued | issued | — |
“pts” = percentage points of year-over-year growth, current release minus previous release.
Merck's Q3 revenue rose 5%, but about $550M of U.S. purchase timing made up roughly two-thirds of the increase, and Keytruda is 47% of sales.
Forensic equity research on US stocks. No spam, unsubscribe anytime.
